Symposium highlights new emerging therapies for the treatment of lupus

Main Category: Lupus
Article Date: 19 Oct 2004 - 0:00 PDT

email to a friend   printer friendly   opinions  

No new treatments for lupus in more than 30 years

WHAT & WHY:

Lupus treatments will be highlighted during a symposium at this year's American College of Rheumatology (ACR) annual scientific meeting in San Antonio, TX. The symposium, "The Emerging Role of Antimetabolites in the Treatment of Nonrenal Systemic Lupus Erythematosus (SLE)," will include discussion of non-FDA approved agents under investigation for the treatment of renal or nonrenal SLE.

Additional discussion topics include current FDA approved, and newer treatments for SLE, and their associated risk: benefit profiles, benefits of newer treatments over current "gold standards" of SLE therapy, the role of antimetabolites in treating renal and nonrenal SLE and the dermatologic, cardiovascular and central nervous system issues in managing patients with SLE.

Lupus statistics:

-- Approximately 1.4 million Americans have been diagnosed with lupus
-- Women are 8-10 times more likely to suffer from lupus than men
-- Lupus occurs primarily in women in their childbearing years
-- Lupus is 3 times more common in African-American women; it is also more common in women of Hispanic, Asian and Native American descent

SPEAKERS:

David M. Eisenberg, MD
Osher Institute, Harvard Medical School
Boston, MA

Anthony Allison, MD
SurroMed Inc.
Menlo Park, CA

Kevin G. Moder, MD
Mayo Clinic
Rochester, MN

Victoria Werth, MD
University of Pennsylvania
Philadelphia, PA

Betty Diamond, MD
Albert Einstein College of Medicine
Bronx, NY

Bevra Hahn, MD
David Geffen School of Medicine
Los Angeles, CA

WHEN AND WHERE:
Thursday, October 21 12:30 PM
Marriott Rivercenter Hotel
Grand Ballroom, Salons H, K and L

FOR MORE INFORMATION/ ARRANGE INTERVIEWS:
Jen Acer
Ketchum
732-266-4450 (on site during ACR)
jennifer.acer@ketchum.com

CJ Martinez
Ketchum
310-980-5431 (on site during ACR)
cj.martinez@ketchum.com

http://www.ketchumcomms.co.uk

This symposium is supported by an unrestricted educational grant from Aspreva Pharmaceuticals.

• Additional
• References
• Citations